News

Bedfont®, a world leader in breath analysis, has been recognised as one of Investec Direct Lending's selected investments for 2025 following Keensight Capital's majority investment in the company. The inclusion highlights Bedfont's position as a leading UK medical technology innovator...

Showcasing the NObreath® and Smokerlyzer® range while connecting with research teams and global distribution partners at Europe's leading respiratory congress. Bedfont® Scientific Limited, a world leader in breath analysis, is excited to be attending this year's European Respiratory Society (ERS)...

The Gastrolyzer® forum has now been replaced by our Gastrolyzer® Educational Portal. The forum previously provided a space for healthcare professionals using the Gastrolyzer® devices to communicate and share knowledge. The updated Gastrolyzer® Educational Portal has been designed to offer...

Traditionally, people associate quitting smoking with national events like Stoptober and New Year's resolutions, but quitting smoking doesn’t have to wait until then. As the summer holiday season draws to an end and people settle back into everyday routines, late...

Over 1,200 NObreath® FeNO devices sold since the 2024 UK guideline update. Bedfont® Scientific Limited, an innovative leader in breath analysis and Fractional exhaled Nitric Oxide (FeNO) testing for asthma care with the NObreath®, welcomes the news that over 1...

Asthma is a chronic disease that affects millions worldwide, with many dying from the condition every year1. Asthma care has evolved over the years, but despite the advances, objectively assessing airway inflammation, the key driver of asthma, remains challenging in...